ICBMT 2025

HOME

Scientific Program

SELECT AND VIEW SESSIONS OF YOUR CHOICE
Search

Oral Presentation 1

 Room A
(1F)
Date & Time Sep. 11 (Thu), 09:00-10:00
Chair(s) Yeon Jung Lim (Chungnam National University College of Medicine)
Dae Sik Kim (Korea University College of Medicine)
Speaker(s) 09:00-09:10 Comparative Analysis of Pretransplant Reduced Toxicity Conditioning Regimens Using TBI vs. Non-TBI in Adult Patients with Acute Lymphoblastic Leukemia Kyung Won Park (College of Medicine, The Catholic University of Korea)
09:10-09:20 A Real-World Data Analysis Comparing Total Body Irradiation versus Chemotherapy Conditioning in Pediatric Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Jae Won Yoo (College of Medicine, The Catholic University of Korea)
09:20-09:30 Comparative Analysis between Imatinib-Based versus Ponatinib-Based Frontline Therapy in Adult Patients with Ph-Positive Acute Lymphoblastic Leukemia Kyoung Il Min (College of Medicine, The Catholic University of Korea)
09:30-09:40 Single-Center Experience of 87 Pediatric T-ALL Patients Receiving Allogeneic HSCT: Superior Survival in CR1 with Protective cGVHD Senlin Zhang (Children's Hospital of Soochow University)
09:40-09:50 Treatment of Post-Transplantation Relapse in Patients with Acute Lymphoblastic Leukemia in the Era of Various Targeted Agents: Transplantation or Not Jaehyun Ahn (College of Medicine, The Catholic University of Korea)
09:50-10:00 Clinical Outcomes of CD19/CD22 CAR-T versus Blinatumomab as Bridging Therapy to Allo-HSCT in Pediatric r/r B-ALL Zihan Chen (Children's Hospital of Soochow University)

Oral Presentation 2

 Room B
(1F)
Date & Time Sep. 11 (Thu), 09:00-10:00
Speaker(s) 09:00-09:10 RNA Sequencing Based Fusion Detection in Acute Myeloid Leukemia: From Clinical Validation to Interpretation Strategies Namsoo Kim (Aerospace Medical Center)
09:10-09:20 Validation of Harmonized Criteria for Transplant-Associated Thrombotic Microangiopathy: A Reassessment of Diagnosis and Prognosis in AML Patients Seonghan Lee (College of Medicine, The Catholic University of Korea)
09:20-09:30 Real-World Outcomes of Allogeneic Transplantation in AML Patients Aged 70 and Older by Remission Status Ka Young Kim (College of Medicine, The Catholic University of Korea)
09:30-09:40 Prognostic Significance of Multi-Parametric MRD and Clinical Integration in CBF-AML Undergoing Autologous Hematopoietic Stem Cell Transplantation Hohyung Nam (College of Medicine, The Catholic University of Korea)
09:40-09:50 A Nationwide Multicenter Registry Analysis of Allogeneic Transplantation in Older Adults with AML in Korea Daehun Kwag (College of Medicine, The Catholic University of Korea)
09:50-10:00 Molecular-Measurable Residual Disease (MRD) During Induction and Consolidation Has Better Prognostic Value than Flow-MRD in Predicting Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia Dingding Dong (Beijing Children’s Hospital, Capital Medical University)

Oral Presentation 3

 Room C
(2F)
Date & Time Sep. 11 (Thu), 09:00-10:00
Chair(s) Sun-Young Kong (National Cancer Center)
Byung-Su Kim (College of Medicine, The Catholic University of Korea)
Speaker(s) 09:00-09:10 Focusing on FLT4 to Exploit Anti-Leukemic Precision Medicine through Integrative Immunomodulatory Tools within the Marrow Microenvironment Su Jung Park (College of Medicine, The Catholic University of Korea)
09:10-09:20 Transcriptomic Insights into Mesenchymal Stem Cell-Derived Exosome-Mediated Ex Vivo Expansion of Hematopoietic Stem Cells Kunye Kwak (Korea University College of Medicine)
09:20-09:30 Stable and Relatively Effective Engraftment of Bone Marrow Stromal Cells in a Murine Model of Syngeneic and Allogeneic Bone Marrow Transplantation Aleksei Bigildeev (National Medical Research Center for Hematology)
09:30-09:40 Targeted Gene Sequencing Identifies a High-Risk Subgroup and Associated Gene Signature in Diffuse Large B-Cell Lymphoma Ho Cheol Jang (Chonnam National University Medical School)
09:40-09:50 Predictive Molecular Biomarkers for Hypomethylating Agent Response in AML Patients through Integrative Omics Analysis Taek Gyu Lee (Yonsei University College of Medicine)
09:50-10:00 Establishment of a Novel Culture Protocol for the Large-Scale Generation of Functional Third-Party-Derived Multivirus-Specific T Cells Takahiro Tomoda (Institute of Science Tokyo (SCIENCE TOKYO))

Oral Presentation 4

 Room D
(2F)
Date & Time Sep. 11 (Thu), 09:00-10:00
Chair(s) Jeong A Kim (College of Medicine, The Catholic University of Korea)
Hyoung Soo Choi (Seoul National University College of Medicine)
Speaker(s) 09:00-09:10 Racial Disparity in Myeloablative Hematopoietic Cell Transplantation Outcomes in Patients with Hematological Malignancies Older Than 45 Years Deepesh Lad (Leukemia/Bone Marrow Transplant Program of British Columbia)
09:10-09:20 Adverse Events to Cryopreserved Hematopoietic Stem Cell Infusion: Experience from a Single Institution Chieh-Wen Kuo (National Taiwan University Children's Hospital)
09:20-09:30 Reduced Dose Post Transplant Cyclophosphamide Regimes as Standard Graft Versus Host Disease Prophylaxis in Haploidentical Stem Cell Transplant in Acute Leukaemia; Real World Experience in National Transplant Centre in Malaysia Tien Gen Wong (Hospital Ampang)
09:30-09:40 Successful Outcome of Haploidentical Hematopoietic Stem Cell Transplantation in Children and Adolescents with Low Dose Post-Transplant Cyclophosphamide and Anti-thymocyte Globulin Hee Young Ju (Sungkyunkwan University School of Medicine)
09:40-09:50 Ex Vivo ab+ T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation with Treosulfan Conditioning in Pediatric Primary HLH: A Comparative Analysis with Matched Donors Sung Han Kang (University of Ulsan College of Medicine)
09:50-10:00 Modified EASIX Score on Day 7 Predicts Survival and Non-Relapse Mortality in Pediatric Acute Leukemia Undergoing Haploidentical Stem Cell Transplantation Kai Cui (Children's Hospital of Soochow University)

Plenary Session 1

Sep. 11 (Thu), 10:30-11:50 		Room A
(1F)
Chair(s) Nack-Gyun Chung (College of Medicine, The Catholic University of Korea)
  • Warren D. Shlomchik

    10:30-11:10

    Local Maintenance of GVHD by Progenitor-like T Cells

    Warren D. Shlomchik

    University of Pittsburgh School of Medicine, USA

  • Hyoung Jin Kang

    11:10-11:50

    Optimization of Hematopoietic Stem Cell Transplantation using Drugs and Cellular Therapies

    Hyoung Jin Kang

    Seoul National University College of Medicine, Korea

Luncheon Symposium 1

Sep. 11 (Thu), 12:00-12:40 		Room A
(1F)
Chair(s) Won-Sik Lee (Inje University College of Medicine)
  • Jiong Hu

    12:00-12:40

    Belumosudil for Severe cGVHD: Insights from a Real-World Observational Study

    Jiong Hu

    Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China

Luncheon Symposium 2

Sep. 11 (Thu), 12:00-12:40 		Room B
(1F)
Chair(s) Kihyun Kim (Sungkyunkwan University School of Medicine)
  • Tadao Ishida

    12:00-12:40

    Optimizing Treatment with Teclistamab in Triple Class-Exposed Multiple Myeloma: Highlighting the MajesTEC-1 Asian Results and Clinical Experience

    Tadao Ishida

    Japanese Red Cross Medical Center, Japan

Luncheon Symposium 3

Sep. 11 (Thu), 12:00-12:40 		Room C
(2F)
Chair(s) Hee-Je Kim (College of Medicine, The Catholic University of Korea)
  • Ofir Wolach

    12:00-12:40

    Venetoclax + HMA in 1L Unfit AML: Bridging Clinical Trials and Real-World Practice

    Ofir Wolach

    Davidoff Cancer Center, Rabin Medical Center, Israel

Luncheon Symposium 4

Sep. 11 (Thu), 12:00-12:40 		Room D
(2F)
Chair(s) Jin Seok Kim (Yonsei University College of Medicine)
  • Shinsuke Iida

    12:00-12:40

    A New Horizon of Multiple Myeloma Treatments Focusing on Elrexfio® Clinical Data

    Shinsuke Iida

    Nagoya City University Graduate School of Medical Sciences, Japan

Plenary Session 2

Sep. 11 (Thu), 13:00-14:20 		Room A
(1F)
Chair(s) Hee-Je Kim (College of Medicine, The Catholic University of Korea)
  • Peihua Lu

    13:00-13:40

    New Concepts and Future Perspectives of CD7 CAR T-cell Therapy for Hematologic Malignancy

    Peihua Lu

    Lu Daopei Hospital, China

  • Leo Luznik

    13:40-14:20

    Post-Transplantation Cyclophosphamide: From Revolution to Evolution in Allogeneic HSCT

    Leo Luznik

    Baylor College of Medicine, USA

Joint Symposium 1 (ASTCT-KSBMT)

Sep. 11 (Thu), 14:30-16:00 		Room A
(1F)
Chair(s) Ho Joon Im (University of Ulsan College of Medicine)
Ryotaro Nakamura (City of Hope National Medical Center)
  • Ryotaro Nakamura

    14:30-15:00

    Conditioning Intensity and the Role of TBI: Disease Control vs. GVHD Risk

    Ryotaro Nakamura

    City of Hope National Medical Center, USA

  • Stefan O. Ciurea

    15:00-15:30

    Optimization of Donor and GVHD Prophylaxis with New Agents in the PTCY Era

    Stefan O. Ciurea

    University of California, Irvine, USA

  • Jae-Ho Yoon

    15:30-16:00

    Evolution and Optimization of Conditioning Regimens in Acute Leukemia: A Korean Perspective

    Jae-Ho Yoon

    College of Medicine, The Catholic University of Korea, Korea

Scientific Session 1

Sep. 11 (Thu), 14:30-16:00 		Room B
(1F)
Chair(s) Deok Hwan Yang (Chonnam National University Medical School)
Dok Hyun Yoon (University of Ulsan College of Medicine)
  • Byoung Ryu

    14:30-15:00

    In vivo CAR-T Cell Generation

    Byoung Ryu

    Legend Biotech, USA

  • 15:00-15:30

    Cancer Immunotherapy by γδ T Cells

    Legend Biotech, USA

  • Duck Cho

    15:30-16:00

    Enhancing anti-CD19 CAR-T/-NK Therapies by Mitigating Trogocytosis and Promoting Serial Killing

    Duck Cho

    Sungkyunkwan University School of Medicine, Korea

Scientific Session 2

Sep. 11 (Thu), 14:30-16:00 		Room C
(2F)
Chair(s) Joon Seong Park (Ajou University School of Medicine)
Young Rok Do (Keimyung University School of Medicine)
  • Austin Kulasekararaj

    14:30-15:00

    HSCT Guidelines for Aplastic Anemia: Optimizing Strategies in the Era of Novel Agents

    Austin Kulasekararaj

    King's College Hospital NHS Foundation Trust, UK

  • Piyanuch Kongtim

    15:00-15:30

    Treatment of Patients with Donor-Specific Anti-HLA Antibodies

    Piyanuch Kongtim

    University of California, Irvine, USA

  • Ji Eun Jang

    15:30-16:00

    The Effect of Donor Age on HSCT Outcomes

    Ji Eun Jang

    Yonsei University College of Medicine, Korea

Education Session 1

Sep. 11 (Thu), 14:30-16:00 		Room D
(2F)
Chair(s) Hyeon-Seok Eom (National Cancer Center)
Seongsoo Jang (University of Ulsan College of Medicine)
  • Saeam Shin

    14:30-15:00

    MRD Monitoring after HSCT

    Saeam Shin

    Yonsei University College of Medicine, Korea

  • Gi June Min

    15:00-15:30

    Optimizing Peripheral Blood Stem Cell Mobilization and Collection

    Gi June Min

    College of Medicine, The Catholic University of Korea, Korea

  • Hee Young Ju

    15:30-16:00

    Epstein-Barr Virus-Associated Lymphoma: Current Understanding and Treatment Strategies

    Hee Young Ju

    Sungkyunkwan University School of Medicine, Korea

Joint Symposium 2 (EBMT-KSBMT)

Sep. 11 (Thu), 16:40-18:20 		Room A
(1F)
Chair(s) Seong Kyu Park (Soonchunhyang University College of Medicine)
Anna Sureda (Catalan Institute of Oncology)
  • Sebastian Giebel

    16:40-17:05

    CAR-T Cell Therapy in RR B-ALL

    Sebastian Giebel

    Maria Sklodowska-Curie National Research Institute of Oncology, Poland

  • Gloria Iacoboni

    17:05-17:30

    CAR-T Cell Therapy in B-Cell Lymphoma

    Gloria Iacoboni

    Vall d’Hebron University Hospital, Spain

  • Sang Eun Yoon

    17:30-17:55

    Current Status of CAR-T and Experiences in Korea

    Sang Eun Yoon

    Sungkyunkwan University School of Medicine, Korea

  • Jae Wook Lee

    17:55-18:20

    Allogeneic HSCT after CAR-T Cell Therapy

    Jae Wook Lee

    College of Medicine, The Catholic University of Korea, Korea

Scientific Session 3

Sep. 11 (Thu), 16:40-18:10 		Room B
(1F)
Chair(s) Chul Won Choi (Korea University College of Medicine)
Jin Seok Kim (Yonsei University College of Medicine)
  • Daniel Royston

    16:40-17:10

    Transforming Hematopathology: AI-Driven Insights into Myeloproliferative Neoplasm

    Daniel Royston

    University of Oxford, UK

  • Jan-Niklas Eckardt

    17:10-17:40

    Artificial Intelligence in Hematology and Oncology

    Jan-Niklas Eckardt

    University Hospital Dresden, Germany

  • Sang-Hyun Hwang

    17:40-18:10

    Application of Large Language Models in Hematology Research and Scientific Writing

    Sang-Hyun Hwang

    University of Ulsan College of Medicine, Korea

Scientific Session 4

Sep. 11 (Thu), 16:40-18:10 		Room C
(2F)
Chair(s) Sung-Soo Yoon (Seoul National University College of Medicine)
Myung Geun Shin (Chonnam National University Medical School)
  • Steven Chan

    16:40-17:10

    Therapeutic Targeting of Clonal Hematopoiesis

    Steven Chan

    University of Toronto, Canada

  • Daichi Inoue

    17:10-17:40

    Understanding and Targeting Poor-Prognostic Leukemia through Physiologically Relevant Animal Models and Integrative Functional Screens

    Daichi Inoue

    The University of Osaka, Japan

  • Youngil Koh

    17:40-18:10

    Clonal Hematopoiesis in Human Disease: From Non-Malignant Disease to Malignancy

    Youngil Koh

    Seoul National University College of Medicine, Korea